CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.
An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
目前治疗策略不断进步，使多发性骨髓瘤（MM）管理随时间取得难以预测的改善。然而，近年来治疗耐药已日益成为重大问题，尤其是来那度胺耐药，以及近来即使在一线治疗中也出现达雷妥尤单抗和来那度胺双重耐药。这使复发/难治性MM患者、特别是首次复发时最佳治疗流程的确定更加复杂。本综述聚焦于在来那度胺方案或达雷妥尤单抗联合来那度胺方案治疗期间或之后进展的MM患者的当前治疗策略。人们高度期待下一代免疫疗法即将面世，同时期待对耐药机制有更深入的认识。与此同时，近期研究结果令人鼓舞，新药有望获批并扩充当前MM治疗药物库，使未来有望实现潜在治愈的目标更近一步。
Current treatment strategies have led to unpredictable improvements in the management of multiple myeloma (MM) over time.
However, resistance to therapy, particularly regarding lenalidomide refractoriness and, more recently, daratumumab and lenalidomide refractoriness, even in the first-line setting, has become an increasingly significant issue in recent years. This resistance complicates the identification of the optimal treatment algorithm for patients with relapsed/refractory MM, particularly at first relapse. In this review, we focus on current strategies for MM patients progressing on or after lenalidomide-based and daratumumab-lenalidomide-based regimens.
The forthcoming availability of next-generation immunotherapies, along with a deeper understanding of resistance mechanisms, is highly anticipated. Meanwhile, based on promising results from recent studies, the approval of novel drugs to expand the current therapeutic armamentarium against MM is bringing us closer to the goal of making a potential cure for the disease much more achievable in the hopefully near future.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
